A study looking at treatment outcomes of pazopanib for advanced kidney cancer (PRINCIPAL)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Kidney cancer
Renal cell cancer




Phase 4

This study is looking to see if pazopanib (Votrient) helps people with advanced kidney cancer.

Pazopanib is a type of biological therapy. It works by blocking signals that tell cancer cells to grow. It is one of the drugs that doctors can use to treat advanced kidney cancer.

The researchers want to find out more information about how well pazopanib works and how it affects quality of life Open a glossary item.

Taking part in this study will not affect your treatment, as your doctor will be prescribing this drug for you whether or not you join the study. But the information they gather from the study may help doctors learn more about pazopanib.  

Who can enter

You may be able to enter this trial if

  • You have renal cell cancer that is mostly clear cell type and has spread to another part of your body
  • Your doctor has decided to treat your cancer with pazopanib and you start treatment within a month of agreeing to take part in this study
  • You are at least 18 years old

You cannot enter this trial if you

  • Are already having treatment as part of another clinical trial
  • Have already had treatment for your advanced kidney cancer with a drug that blocks cancer growth signals (such as sunitinib or everolimus), or a drug that blocks the growth of blood vessels to the cancer, for example bevacizumab   

Trial design

This is an international phase 4 study. It will recruit between 700 and 1,000 people from different countries around the world. This is an observational study.

You take pazopanib as directed by your doctor.

For 2½ years your doctor will send information about your health and medications to the study team.

The study team will ask you to fill out 3 questionnaires when you first agree to take part in this study, and then every 3 months for 2½ years. These questionnaires will ask about side effects and how you’ve been feeling. This is called a quality of life study.

Hospital visits

There are no extra visits if you take part in this study.

Side effects

The most common side effects of pazopanib are

We have information about the side effects of pazopanib in our cancer drugs section.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Robert Hawkins

Supported by

GlaxoSmithKline (GSK)
NIHR Clinical Research Network: Cancer

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 9725

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think